Academic Journal
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
| العنوان: | Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer |
|---|---|
| المؤلفون: | Prager, Gerald W., Taieb, Julien, Fakih, Marwan, Ciardiello, Fortunato, Van Cutsem, Eric, Elez, Elena, Cruz, Felipe M., Wyrwicz, Lucjan, Stroyakovskiy, Daniil, Pápai, Zsuzsanna, Poureau, Pierre Guillaume, Liposits, Gabor, Cremolini, Chiara, Bondarenko, Igor, Modest, Dominik P., Benhadji, Karim A., Amellal, Nadia, Leger, Catherine, Vidot, Loïck, Tabernero, Josep |
| المصدر: | Prager , G W , Taieb , J , Fakih , M , Ciardiello , F , Van Cutsem , E , Elez , E , Cruz , F M , Wyrwicz , L , Stroyakovskiy , D , Pápai , Z , Poureau , P G , Liposits , G , Cremolini , C , Bondarenko , I , Modest , D P , Benhadji , K A , Amellal , N , Leger , C , Vidot , L & Tabernero , J 2023 , ' Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer ' , New .... |
| سنة النشر: | 2023 |
| المجموعة: | Aarhus University: Research |
| مصطلحات موضوعية: | Gastroenterology, Gastrointestinal Tract Cancer, Hematology/Oncology, Treatments in Oncology |
| الوصف: | Background In a previous phase 3 trial, treatment with trifluridine-tipiracil (FTD-TPI) prolonged overall survival among patients with metastatic colorectal cancer. Preliminary data from single-group and randomized phase 2 trials suggest that treatment with FTD-TPI in addition to bevacizumab has the potential to extend survival. Methods We randomly assigned, in a 1:1 ratio, adult patients who had received no more than two previous chemotherapy regimens for the treatment of advanced colorectal cancer to receive FTD-TPI plus bevacizumab (combination group) or FTD-TPI alone (FTD-TPI group). The primary end point was overall survival. Secondary end points were progression-free survival and safety, including the time to worsening of the Eastern Cooperative Oncology Group (ECOG) performance-status score from 0 or 1 to 2 or more (on a scale from 0 to 5, with higher scores indicating greater disability). Results A total of 246 patients were assigned to each group. The median overall survival was 10.8 months in the combination group and 7.5 months in the FTD-TPI group (hazard ratio for death, 0.61; 95% confidence interval [CI], 0.49 to 0.77; P<0.001). The median progression-free survival was 5.6 months in the combination group and 2.4 months in the FTD-TPI group (hazard ratio for disease progression or death, 0.44; 95% CI, 0.36 to 0.54; P<0.001). The most common adverse events in both groups were neutropenia, nausea, and anemia. No treatment-related deaths were reported. The median time to worsening of the ECOG performance-status score from 0 or 1 to 2 or more was 9.3 months in the combination group and 6.3 months in the FTD-TPI group (hazard ratio, 0.54; 95% CI, 0.43 to 0.67). Conclusions Among patients with refractory metastatic colorectal cancer, treatment with FTD-TPI plus bevacizumab resulted in longer overall survival than FTD-TPI alone. (Funded by Servier and Taiho Oncology; SUNLIGHT ClinicalTrials.gov number, NCT04737187; EudraCT number, 2020-001976-14.). |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| DOI: | 10.1056/NEJMoa2214963 |
| الاتاحة: | https://pure.au.dk/portal/en/publications/e113bf09-1e9a-4a4f-ac51-c0889d13237e https://doi.org/10.1056/NEJMoa2214963 https://pure.au.dk/ws/files/411944716/Trifluridine-Tipiracil_and_Bevacizumab_in_Refractory_Metastatic_Colorectal_Cancer.pdf http://www.scopus.com/inward/record.url?scp=85159544588&partnerID=8YFLogxK |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.5FFD4B03 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1056/NEJMoa2214963 |
|---|